Nanobiotix announces publication of phase III Soft Tissue Sarcoma data for first-in-class NBTXR3 in the Lancet Oncology

NEXT STORY
ABOG Appoints New Board of Directors Members, Division Chair, and Members of Subspecialty Divisions
PREV STORY
Emergency Medical Service Products Market Size Worth Around US$ 24.3 Bn by 2026
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

pSivida Announces FDA Acceptance For Filing of New Drug Application (NDA) for Durasert™ Three-Year Treatment for Posterior Segment Uveitis

WATERTOWN, Mass., March 19, 2018 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader ...

author_avatar
NASDAQ Market News

TG Therapeutics Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ® at the 2021 European Hematology Association Virtual Congress

author_avatar
NASDAQ Market News

Vaccinex Presents Updated Interim Data from a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer in Podium and Poster Presentations at the Fifth International Cancer lmmunotherapy Conference in Paris, France

author_avatar
NASDAQ Market News